Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FertistartKit is a human menopausal gonadotropin (HMG) preparation used for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies (ART) such as IVF. It contains highly purified follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, specifically supplemented with human chorionic gonadotropin (hCG) to provide stable LH-like activity. Developed and manufactured by IBSA, it is used to stimulate the development of multiple follicles in women, particularly those identified as poor ovarian responders. In the BISTIM clinical trial sponsored by Centre Hospitalier Intercommunal Creteil, FertistartKit was used to compare the efficacy of dual ovarian stimulation (DUOSTIM) against conventional stimulation protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FertistartKit.